SALT
LAKE CITY, March 11, 2025 /PRNewswire/
-- Sera Prognostics Inc., The Pregnancy Company®
(NASDAQ: SERA), focused on improving maternal and neonatal health
by providing innovative pregnancy biomarker information to doctors
and patients, today announced that it will report fourth quarter
and full year 2024 financial results on Wednesday, March 19, 2025, after the close of the
market. The Company will host a corresponding conference call and
live webcast to discuss operational highlights, financial results
and key topics at 5:00 p.m. Eastern
Time. A press release outlining the financial results and
highlights will be publicly distributed before the call.
Conference Call Details:
US domestic callers: (800) 836-8184
International callers: (646) 357-8785
Webcast Registration Link:
https://app.webinar.net/2velx8K3AMB
Live audio of the webcast will be available online from the
Investors page of the Company's website at www.seraprognostics.com.
The webcast will be archived on the Investors page and will be
available for one year.
About Sera Prognostics, Inc.
Sera Prognostics is a leading health diagnostics company
dedicated to improving the lives of women and babies through
precision pregnancy care. Sera's mission is to provide early,
pivotal pregnancy information to improve the health of mothers and
newborns, resulting in reductions in the costs of healthcare
delivery. Sera has a robust pipeline of innovative diagnostic tests
focused on the early prediction of preterm birth risk and other
complications of pregnancy. Sera's precision medicine PreTRM® Test
reports to a physician the individualized risk of spontaneous
premature delivery in a pregnancy, enabling earlier proactive
interventions in women with higher risk. Sera Prognostics is
headquartered in Salt Lake City, Utah.
About Preterm Birth
Preterm birth is defined as any birth before 37 weeks' gestation
and is the leading cause of illness and death in newborns. The 2023
March of Dimes Report Card shows that, for the last five
consecutive years, more than one in ten infants is born prematurely
in the United States.
Prematurity is associated with a significantly increased risk of
major long-term medical complications, including learning
disabilities, cerebral palsy, chronic respiratory illness,
intellectual disability, seizures, and vision and hearing loss, and
can generate significant costs throughout the lives of affected
children. The annual health care costs to manage short- and
long-term complications of prematurity in the United
States were estimated to be approximately $25
billion for 2016.
About the PreTRM® Test
The PreTRM® Test is the only broadly validated, commercially
available blood-based biomarker test that provides an early,
accurate and individualized risk prediction for spontaneous preterm
birth in asymptomatic singleton pregnancies. The PreTRM® Test
measures and analyzes proteins in the blood that are highly
predictive of preterm birth. The PreTRM® Test permits physicians to
identify, during the weeks 18 through 20 of pregnancy, which women
are at increased risk for preterm birth and its complications,
enabling more informed, personalized clinical decisions based on
each woman's individual risk. The PreTRM® Test is ordered by a
medical professional.
Sera Prognostics, the Sera Prognostics logo, The Pregnancy
Company, and PreTRM are trademarks or registered trademarks of Sera
Prognostics, Inc. in the United States and/or other
countries.
Safe Harbor Statement
This press release contains "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of
1995, including statements relating to the date, time and content
of the Company's quarterly earnings release and conference call;
availability of the live audio of the conference call on the
Company's website; and the company's strategic directives under the
caption "About Sera Prognostics, Inc." These "forward-looking
statements" are based on management's current expectations of
future events and are subject to a number of risks and
uncertainties that could cause actual results to differ materially
and adversely from those set forth in or implied by forward-looking
statements. These risks and uncertainties include, but are not
limited to: net losses, cash generation, and the potential need to
raise more capital; revenues from the PreTRM Test representing
substantially all Company revenues to date; the need for broad
scientific and market acceptance of the PreTRM Test; a concentrated
number of material customers; our ability to introduce new
products; potential competition; our proprietary biobank; critical
suppliers; the COVID-19 pandemic and its potential lingering impact
on our operations, as well as the business or operations of third
parties with whom we conduct business; estimates of total
addressable market opportunity and forecasts of market growth;
potential third-party payer coverage and reimbursement; new
reimbursement methodologies applicable to the PreTRM Test,
including new CPT codes and payment rates for those codes; changes
in FDA regulation of laboratory-developed tests; the intellectual
property rights protecting our tests and market position; and other
factors discussed under the heading "Risk Factors" contained in our
Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed
with the Securities and Exchange Commission, as well as any updates
to those risk factors filed from time to time in our periodic and
current reports filed with the Securities and Exchange Commission.
All information in this press release is as of the date of the
release, and the Company undertakes no duty to update this
information unless required by law.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/sera-prognostics-announces-conference-call-and-webcast-of-fourth-quarter-and-fiscal-year-2024-financial-results-on-march-19-2025-302397722.html
SOURCE Sera Prognostics, Inc.
